Evidence map›Paper›PMID 42613484›Full record

ArticleDigestive diseases and sciences2026

Higher Off-Therapy Relapse Risk with Tenofovir Alafenamide than Entecavir in Non-cirrhotic HBeAg-Negative Chronic Hepatitis B: Insights from End-of-Treatment qHBsAg Stratification.

Yi-Jie Huang, Chung-Hsin Chang, Shou-Wu Lee, Chun-Fang Tung, Szu-Chia Liao, Teng-Yu Lee, Yen-Chun Peng, Jun-Sing Wang

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yi-Jie HuangSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, 112304, Taiwan.
Chung-Hsin ChangDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, 407219, Taiwan.
Shou-Wu LeeDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, 407219, Taiwan.
Chun-Fang TungDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, 407219, Taiwan.
Szu-Chia LiaoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, 407219, Taiwan.
Teng-Yu LeeDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, 407219, Taiwan.
Yen-Chun PengDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, 407219, Taiwan.
Jun-Sing WangSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, 112304, Taiwan. jswang@vghtc.gov.tw.ORCID https://orcid.org/0000-0002-0887-6432

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsEnd-of-treatment (EOT) qHBsAg predicts off-therapy relapse in HBeAg-negative chronic hepatitis B (CHB), but whether its stratifying ability differs between entecavir (ETV) and tenofovir alafenamide (TAF) remains unclear. This study compared 12-month relapse risk across EOT qHBsAg strata after ETV or TAF discontinuation in non-cirrhotic HBeAg-negative CHB patients.

methodsIn this retrospective cohort study, non-cirrhotic HBeAg-negative CHB patients discontinuing ETV or TAF were 1:1 propensity score matched. Virological relapse was assessed by Kaplan-Meier analysis and Cox regression; clinical relapse by cumulative incidence functions with Fine-Gray competing risks regression. Hazard ratios and subdistribution hazard ratios (sHRs) were compared across EOT qHBsAg strata (< 2, 2-3, ≥3 log

resultsA total of 130 patients (65 per group) were analyzed. Among ETV discontinuers, clinical relapse rates increased progressively with higher EOT qHBsAg (0.0%, 14.6%, and 25.0% for <2, 2-3, and ≥3 log

conclusionsEOT qHBsAg effectively stratifies clinical relapse risk after ETV discontinuation but shows limited discriminative ability after TAF cessation, where relapse rates remain uniformly high across all qHBsAg levels.

Indexed as

AdenineAntiviral AgentsGuanineHepatitis B, ChronicHepatitis B e AntigensTenofovirAdultAlanineFemaleHumansMaleMiddle AgedRecurrenceRetrospective StudiesRisk FactorsTreatment InterruptionAdenineAlanineAntiviral AgentsentecavirGuanineHepatitis B e AntigensTenofovirtenofovir alafenamideChronic hepatitis BClinical relapseNucleos(t)ide analogue discontinuationQuantitative hepatitis B surface antigen

Identifiers

PMID42613484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.